BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal

BMS and Hengrui Forge $15.2 Billion Onco-Immune Partnership

Bristol Myers Squibb (BMS) and Hengrui Pharma have announced a strategic partnership to develop 13 investigational therapies for various cancers, immune-mediated, and blood-related diseases. BMS will provide $950 million in upfront and near-term payments, comprising a $600 million upfront payment and two $175 million commitments payable at the first and second anniversaries. The total deal value could reach $15.2 billion, including exercise option fees and potential development, regulatory, and commercial milestones. The agreement, expected to close in the third quarter, involves Hengrui contributing four oncology and hematology candidates, BMS providing four immune-mediated molecules, and five programs being jointly discovered.

• The collaboration is valued at up to $15.2 billion, driven by potential development, regulatory, and commercial milestones, alongside exercise option fees for certain assets. BMS's initial commitment totals $950 million, including a $600 million upfront payment and two contingent payments of $175 million each, due at the partnership's first and second anniversaries in 2027 and 2028, respectively.
• The partnership aims to advance 13 early-stage investigational therapies across oncology, hematology, and immune-mediated conditions. Hengrui Pharma will contribute four drug candidates focused on oncology and hematology, while Bristol Myers Squibb will provide four molecules for immune-mediated diseases. The remaining five programs will be jointly discovered and developed by both companies.
• The agreement establishes distinct geographical rights for the assets. BMS will hold exclusive worldwide rights for the four Hengrui-originated assets, excluding mainland China, Hong Kong, and Macau. Conversely, Hengrui will gain exclusive rights to the BMS-originated assets within these three markets and will be entitled to tiered royalties on net sales of products outside this 'Hengrui territory.'

How Evolving Oncology and Immunology Landscapes Drive Strategic Alliances

The cancer treatment landscape has undergone profound transformation over the past five years, driven by remarkable advances in precision medicine and immunotherapy. The I-PREDICT study exemplified this shift toward personalized oncology, demonstrating that individually dosed drug combinations targeting multiple molecular alterations could achieve superior outcomes with lower toxicity rates. Of particular significance, 95% of patients exhibited unique molecular landscapes, necessitating 157 different treatment regimens—highlighting the era's movement away from one-size-fits-all approaches toward truly individualized therapy based on tumor-specific genomic profiles.

Immunotherapy developments have revolutionized cancer care, with immune checkpoint inhibitors achieving remarkable success across diverse malignancies. Beyond the established PD-1/PD-L1 inhibitors, new targets including LAG-3, TIGIT, and TIM-3 have emerged to combat immune evasion mechanisms. The integration of artificial intelligence has accelerated biomarker discovery, with machine learning models identifying five key factors predictive of checkpoint inhibitor response: tumor mutation burden, T-cell infiltration, transforming growth factor-beta activity, prior treatment history, and tumor proliferative potential. These predictive tools, validated across multiple independent cohorts, represent a significant advancement in patient selection and treatment optimization.

Targeted therapy and antibody-drug conjugate development have achieved impressive clinical outcomes across multiple tumor types. In breast cancer, trastuzumab deruxtecan demonstrated ORRs near 70% in HER2-positive disease, while sacituzumab govitecan reproduced pivotal trial outcomes in real-world settings. Lung cancer treatment has been transformed by KRAS G12C inhibitors like sotorasib and adagrasib, achieving ORRs of 28-34%, while MET inhibitors have provided durable disease control with PFS around 6-7 months. Notably, the FDA's approval of six new kinase inhibitors in 2025 and the emergence of protein degradation strategies using PROTACs demonstrate the continued expansion of precision oncology tools, offering new therapeutic options for previously intractable malignancies.

Exploring Novel Targets in the Joint Oncology and Immunology Pipeline

Recent research has identified several promising novel therapeutic targets across multiple cancer types, leveraging advanced technologies including drug repurposing, multi-omics approaches, and artificial intelligence-driven target discovery. These emerging targets span diverse biological pathways from protein synthesis regulation to immune checkpoint modulation, offering new opportunities for precision oncology interventions.

• SAG/RBX2/ROC2/RNF7 - An attractive anti-cancer target overexpressed in many human cancer tissues with positive correlation to poor patient survival. Acts as a catalytic subunit of CRL5 and CRL1 to ubiquitylate and degrade tumor suppressor substrates, with small molecule inhibitors and PROTAC degraders currently under development.

• Complement component 5a receptor 1 (C5aR1) - Identified as a novel target of citalopram through drug repurposing approaches in hepatocellular carcinoma. Predominantly expressed by tumor-associated macrophages, targeting C5aR1 enhances local macrophage phagocytosis and elicits CD8 T anti-tumor immunity.

• Eukaryotic elongation factor 1A1 (EEF1A1) - Emerging therapeutic candidate for triple-negative breast cancer identified as a direct binding partner of novel Penicillide-derived inhibitors. This key regulator of protein synthesis through peptide chain elongation represents a promising target for modulating cancer stem cell properties and tumor progression.

• PD-L1 small molecule blockers - Advanced N-terphenylpicolinamide derivatives designed as improved small molecular blockers targeting PD-L1 protein. These optimized molecules activate primary immune cells and demonstrate enhanced elimination of cancer cells that overexpress PD-L1 to evade immune responses.

• Histone deacetylase 6 (HDAC6) - Therapeutic target associated with oncogenic transformation and cancer metastasis, with novel 2,7-diazaphenothiazine core derivatives showing more potent inhibitory activity characterized by stable binding and favorable complex energy profiles.

• miR-218 - MicroRNA target with significant tumor-suppressive properties in lung cancer, serving as both diagnostic biomarker and therapeutic target. Functions as a key regulator of critical cancer progression pathways including proliferation, invasion, metastasis, and apoptosis, with expression levels inversely correlating with tumor aggressiveness.

Targeting Key Unmet Needs in Oncology and Immune-Mediated Diseases

The oncology landscape continues to face significant challenges despite therapeutic advances, with certain cancer types maintaining persistently low 5-year survival rates and treatment resistance remaining a critical barrier. Recent research has identified several key unmet needs and vulnerable populations requiring targeted interventions. These efforts focus on addressing fundamental limitations in current treatment paradigms while developing innovative approaches to overcome resistance mechanisms.

• Hepatocellular carcinoma (HCC) represents a growing unmet need, with incidence rates doubling over recent decades while other cancers trend downward, requiring better understanding of tumor-initiating stem-like cells (TICs) that express pluripotency transcription factors and resist conventional therapies

• Cancer stem cells (CSCs) across multiple tumor types contribute to increased proliferation, metastasis, multidrug resistance, and treatment failure, necessitating combination therapies that integrate immunotherapy with cytotoxic approaches to eliminate both CSCs and non-CSCs

• Chemoresistance remains a major challenge in aggressive cancers including breast, lung, ovarian, pancreatic, bladder, sarcoma, and lymphomas, particularly due to P-glycoprotein overexpression, requiring development of imaging biomarkers to detect resistant cell clones

• Immunotherapy-limited responders represent a significant unmet population, as many patients with malignant tumors show limited response to treatment despite advances in immune checkpoint inhibitors and adoptive cell transfer therapies

• Pediatric, adolescent, and young adult (AYA) patients face pronounced inequalities in clinical trial access across Europe, with only 49% of 436 cancer-directed trials between 2010-2022 exclusively including these populations

• Gynecological malignancies (cervical, endometrial, and ovarian carcinoma) in advanced or metastatic stages remain difficult to treat with poor prognosis, alongside non-small cell lung cancer which leads with 12.4% incidence rate in 2022

BMS Forges Broad Alliance to Fuel Next-Gen Pipeline

Bristol Myers Squibb (BMS) has long been a formidable player in the pharmaceutical landscape, particularly recognized for its pioneering work in immuno-oncology with agents like ipilimumab and nivolumab, which have redefined cancer treatment. Beyond oncology, the company has also made strides in immune-mediated diseases, exemplified by the advanced development of its selective TYK2 inhibitor, deucravacitinib, for conditions such as psoriasis. This latest strategic partnership with Hengrui Pharma, encompassing 13 investigational therapies across cancers, immune-mediated, and blood-related diseases, signals a clear intent to build upon these foundations and secure a robust future pipeline.

The collaboration is a strategic move to diversify and reinforce BMS's portfolio, mitigating the inherent risks associated with relying on a few key products. By bringing together Hengrui's expertise in oncology and hematology with BMS's strengths in immune-mediated molecules, the alliance aims to leverage complementary R&D capabilities. This could accelerate the discovery and development of novel combination therapies, potentially exploring new modalities such as small molecule PD-1/PD-L1 inhibitors and advanced drug delivery systems like nanoparticles, which are showing promise in enhancing immunotherapy efficacy, even in challenging areas like brain metastases.

However, such an ambitious undertaking is not without its considerations. The substantial financial commitment, with a potential total deal value reaching $15.2 billion, represents a significant investment in investigational assets, which inherently carry high development risks. Historically, drug development has faced hurdles in identifying reliable biomarkers for patient selection and managing complex adverse events, including immune-related toxicities associated with immunotherapies. Successfully navigating these challenges across a broad new portfolio will be crucial. Furthermore, the competitive landscape in oncology and immune-mediated diseases is intensifying, and new therapies will need to demonstrate compelling clinical and economic value to gain market acceptance, especially given existing pressures on drug affordability and cost-effectiveness. This partnership, therefore, represents a calculated, yet bold, strategic expansion designed to ensure BMS's continued leadership and innovation in critical therapeutic areas for decades to come.